FDA shortage-resolution notices for semaglutide and tirzepatide
The most effective approach for each patient depends on factors such as metabolic health, lifestyle, treatment tolerance, and personal goals
Ilya Yuffa, EVP and President of Lilly USA, noted on the call that 80% of the roughly 20,000 Foundayo patients treated as of April 30 were new to the GLP-1 class entirely, indicating market expansion rather than share-taking
Water retention and mild joint stiffness are common at 25 mg
These issues can include blurred vision, worsening diabetic retinopathy, and problems related to the optic nerve
Did you disclose your true purpose when obtaining the prescription